

Quick Search Guide


Cortellis HTA Intelligence

Quickly find HTA Reimbursement, Managed Entry Agreement and Label events from 21 markets and 5 Regulatory Authorities using Quick Search in Cortellis HTA Intelligence.

To use Quick search, enter the name of a Disease Condition, Drug, Country, Agency, or Company and then manipulate the variables in the charts to explore and drill down the results.

Example: How do I find HTA events using Quick Search? For this example, let us explore venetoclax.

1. Start typing “venetoclax” into the Quick Search bar and select from the options.
2. Content defaults in the **Market Access Table** and to a Bar chart with Agency and Decision as the X and Y-axis defaults.
3. Change the **X- and Y- axis** drop downs, the **Filter Measure** and **Date range** to drill down and explore the data further.
4. Click **Follow** to setup an email notification.



5. Scroll to view the HTA events below the table from step 3.

Agency: AIFA-I

Expand All Events

Expand All Details

Export to Excel

Share

Status	Decision	Date	Indication	Line of therapy	Reason for decision (clinical)	Restrictions (Category)	AIFA-I Final Assessment on Innovativeness	PDF	Add
Entry In Progress		06/2021		N/A	N/A		N/A		

Agency: AWMSG

Status	Decision	Date	Disease Condition	Indication	Line of therapy	Reason for decision (economic)	Reason for decision (clinical)	Restrictions (Category)	PDF	Add
1 Event	No decision	12/2018	Chronic Lymphocytic Leukemia	In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received a ...	N/A	N/A	N/A			

Agency: CADTH

Status	Decision	Date	Disease Condition	Indication	Line of therapy	Reason for decision (economic)	Reason for decision (clinical)	Restrictions (Category)	PDF	Add
1 Event	Do not recommend	08/2021	Acute Myeloid Leukemia	In combination with low-dose cytarabine, for the treatment of patients with newly diagnosed AML who are ≥ 75 years of age ...	1	Lower cost-effectiveness	Lower efficacy/effectiveness			
1 Event	Recommend with restrictions	08/2021	Acute Myeloid Leukemia	In combination with azacitidine, for the treatment of patients with newly diagnosed AML who are ≥ 75 years of age or hav ...	1	Lower cost	Greater efficacy/effectiveness	Administration, Population		

Agency: Chuikyo

Status	Decision	Date	Disease Condition	Indication	Line of therapy	Reason for decision (economic)	Reason for decision (clinical)	Restrictions (Category)	PDF	Add
1 Event	Recommend (unknown restrictions)	11/2019	Chronic Lymphocytic Leukemia	Treatment of recurrent or refractory chronic lymphocytic leukemia	N/A	N/A	N/A	Label unavailable		

Agency: G-BA

Status	Decision	Date	Disease Condition	Indication	Line of therapy	Reason for decision (economic)	Reason for decision (clinical)	Restrictions (Category)	PDF	Add
9 Events	Recommend	06/2017 - 10/2020	Chronic Lymphocytic Leukemia	In combination with obinutuzumab, for the treatment of adult patients with previously untreated CLL who are not eligible ...	1 (+ 5 more)	N/A	Insufficient evidence (+ 3 more)	No Restrictions		
1 Event	Recommend (unknown restrictions)	12/2021	Acute Myeloid Leukemia	In combination with a hypomethylating agent, for the treatment of adult patients with newly diagnosed AML who are inelig ...	1	N/A	Greater efficacy/effectiveness	Label unavailable		
1 Event	Recommend with restrictions	10/2020	Chronic Lymphocytic Leukemia	In combination with obinutuzumab, for the treatment of adult patients with previously untreated CLL who have 17p deletio ...	1	N/A	Lack of evidence	Population		

For more information contact Customer Service at **LS Product Support**